INDEPENDENCE Spacer for Lumbar Fusion
Circumferential Lumbar Spinal Fusion for Treatment of Degenerative Disc Disease: A Prospective, Non-Randomized Clinical Study
調査の概要
詳細な説明
A total of thirty subjects will be enrolled at Scott & White Healthcare. The INDEPENDENCE spacer will be filled with autogenous bone graft material. The devices subject to this Agreement have received 510(k) clearance from the FDA for the indications specified in this Agreement.
Patients will be followed for 2 years with evaluations at the following time intervals: preoperatively (within 2 months of surgery) and postoperatively at 6 weeks, 3 months, 6 months, 12 months, and 24 months.
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
Texas
-
Temple、Texas、アメリカ、76508
- Scott & White Healthcare
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
• Objective evidence of degenerative disc disease at 1 or 2 level(s) between L2 and S1 with degeneration confirmed by patient history and radiographic examination
- Experience pain, functional deficit and/or neurological deficit for a minimum of six months
- Unresponsiveness to documented non-surgical treatment modalities for a minimum of six months and/or presentation with progressive symptoms of nerve root or spinal cord compression prior to enrollment
- At least 18 years of age and maximum 65 years of age
- Ability to provide Informed Consent for study participation and to return for all follow-up visits
Exclusion Criteria:
• Presence of systemic or localized infection at the site of surgery
- More than 2 levels to be instrumented
- Previous fusion attempt at the involved level(s)
- More than three previous open, posterior, lumbar spinal surgical procedures at the involved level(s)
- Trauma at the level(s) to be fused
- More than grade 1 spondylolisthesis
- Previous documentation of osteopenia, osteoporosis, or osteomalacia to a degree that spinal instrumentation would be contraindicated
- Diagnosis of a condition or requires postoperative medication(s), which may interfere with bony/soft tissue healing
- Presence of a disease entity or condition which totally precludes possibility of bony fusion (e.g. metastatic cancer, HIV, long term use of steroids, etc.)
- Immunosuppressive disorder
- Pregnant or interested in becoming pregnant during the duration of the study
- History of substance abuse (drugs or alcohol)
- Any known allergy to a metal alloy
- Mentally incompetent or prisoner
- Currently a participant in another study
研究計画
研究はどのように設計されていますか？
デザインの詳細
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Radiographic fusion evaluation
時間枠：2 years
|
Anterior Posterior / Lateral, Flexion-Extension X-rays at every timepoint will be evaluated for signs of fusion, pseudoarthrosis and implant subsidence or migration
|
2 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Patient Self- Assessment for pain scores
時間枠：2 years
|
VAS questionnaires to be completed at every follow-up timepoint
|
2 years
|
|
Patient Satisfaction
時間枠：2 years
|
Questionnaire to be completed at every follow-up timepoint
|
2 years
|
協力者と研究者
スポンサー
捜査官
- 主任研究者：Christopher Chaput, MD、Scott & White Healthcare
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。